Mirus Bio Bio-Expo Live February 2026: Upstream Bioprocessing

Adeno-associated virus (AAV) and lentiviral (LV) vectors remain at the forefront of the gene therapy industry, enabling an ever-growing pipeline of therapeutics to target both rare and prevalent diseases. During viral vector manufacturing, the transfection step provides a prime opportunity to advance innovations that preserve performance as processes scale.

In this presentation, learn how you can keep your large-scale transfection process for viral vector manufacturing steady and stable with help from the team of experts at Mirus Bio.